Aileron Therapeutics Gears Up for IPO
Aileron Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Aileron Therapeutics has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company mentioned no pricing details in this filing, but it values its shares up to $69 million. The firm intends to list its shares on the Nasdaq under the symbol ALRN.
The underwriters for the offering were Merrill Lynch, Jefferies, William Blair and Canaccord Genuity.
This clinical-stage biopharmaceutical company is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Its lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers.
[nativounit]
ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2. Its ongoing clinical trials of ALRN-6924 consist of a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2a trial for the treatment of peripheral T-cell lymphoma (PTCL), a Phase 1 trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS) as a monotherapy, and a Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside (Ara-C).
As of March 31, 2017, the firm had cash, cash equivalents, and investments totaled $15.3 million. Aileron intends to use the net proceeds from this offering:
- To fund its ongoing clinical trials of ALRN-6924, including funding for its Phase 1 All-comers trial, funding for its Phase 2a PTCL trial, and funding for its Phase 1/1b AML/MDS trials.
- To fund additional research and clinical development activity related to ALRN-6924 and other programs.
The remainder of the net proceeds will be put toward working capital and other general corporate purposes, which may include funding for additional research, hiring additional personnel, capital expenditures and the costs of operating as a public company.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
